Akido Labs, Inc., the AI and care delivery company reimagining healthcare, announced it has raised $60 million in Series B funding. The round was led by Oak HC/FT with participation from Greco, SNR, and existing investors Y Combinator, Future Communities Capital, Jeff Dean (Chief Scientist, Google DeepMind & Google Research), and the Comprehensive Blood & Cancer Center. Funding will be used to expand the reach of ScopeAI, a system that increases clinical capacity and improves healthcare access.
ScopeAI is transforming how Akido providers practice medicine – enabling them to care for dramatically more patients without compromising on quality. This unlocks time for providers to focus on complex cases, while increasing the total number of patients the system can support. The U.S. population requires over 3 billion doctor visits per year, yet only 825 million are currently available. The result is longer waits, especially for specialists, rushed appointments, and rising rates of preventable disease. Akido is addressing this crisis by embedding powerful medical intelligence directly into the clinical workflow – bringing scale, efficiency, and consistency to the front lines of care.
“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage. With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers, and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography,” said Prashant Samant, Co-Founder & CEO of Akido. “At Akido, we believe exceptional healthcare is a basic human right. Our work has always focused on democratizing high quality healthcare, and this funding enables us to accelerate that mission.”
In a ScopeAI visit, a trained Medical Assistant (MA) meets with a patient, guided by intelligent prompts from ScopeAI throughout the encounter. ScopeAI uses clinical reasoning to actively listen, adapt in real time, and build a comprehensive understanding of the patient’s condition. Its scribing and auditory capabilities allow for dynamic conversation while simultaneously generating a full clinical report, including a preliminary diagnosis, treatment plan, and justification log for each decision it makes. With ScopeAI, providers gain a deeper, more complete picture of a patient’s health with less time spent capturing it. An Akido provider can oversee a team of MAs conducting ScopeAI visits, increasing access to care while enabling the provider to focus on higher-acuity or more complex cases.
Also Read: GE HealthCare debuts CleaRecon DL, AI 3D reconstruction
Akido’s AI-based healthcare visits have delivered 5x more face-to-face time with patients and have achieved a 96 NPS score. With this new funding, Akido will accelerate the development and deployment of ScopeAI throughout its Akido Care medical network of 240 providers across 26 specialties. It will also help support Akido’s entrance into new markets like the recently announced first-of-its-kind healthcare program in New York City that is designed to address specific chronic diseases for professional rideshare and for-hire drivers.
“Akido is delivering on the promise of changing how patients experience a visit with their provider through AI,” said Andrew Adams, Co-Founder & Managing Partner at Oak HC/FT. “With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled. We are excited to partner with their exceptional team of healthcare and technical operators to scale ScopeAI, expanding access to high-quality, AI-powered care for more patients.”
Akido was founded in 2015 with the goal of reimagining healthcare for historically vulnerable communities by leveraging AI and machine learning. In 2022, Akido launched Akido Care, a medical network that today includes nearly 100 clinics, offering primary and specialty care across 26 sub-specialties. This dual strategy is what created the opportunity for Akido to leverage its proprietary dataset of over 10 million patient case studies and reinforcement-loop-human-feedback (RLHF) environment to launch ScopeAI. ScopeAI is one of the most sophisticated clinical AI systems available to providers, and it is continuously refined by incorporating real-time provider feedback. By integrating ScopeAI into the Akido Care medical network, Akido is positioned to empower providers to deliver highly personalized care to an individual patient while also scaling programs at a population level.
Source: Businesswire
